Literature DB >> 12218440

Cardiovascular risk associated with HIV therapy.

Judith S Currier1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12218440     DOI： 10.1097/00126334-200209011-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  6 in total

1.  Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting.

Authors:  C William Wester; John R Koethe; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Hwanhee Hong; Hermann Bussmann; Tendani Gaolathe; Catherine C McGowan; Timothy R Sterling; Richard G Marlink
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection.

Authors:  Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino
Journal:  Circulation       Date:  2018-02-14       Impact factor: 29.690

3.  Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

Authors:  M Aboud; A Elgalib; L Pomeroy; G Panayiotakopoulos; E Skopelitis; R Kulasegaram; C Dimian; F C Lampe; A Duncan; A S Wierzbicki; B S Peters
Journal:  Int J Clin Pract       Date:  2010-08       Impact factor: 2.503

4.  Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Authors:  Philip H Keiser; Michael G Sension; Edwin DeJesus; Allan Rodriguez; Jeffrey F Olliffe; Vanessa C Williams; John H Wakeford; Jerry W Snidow; Anne D Shachoy-Clark; Julie W Fleming; Gary E Pakes; Jaime E Hernandez
Journal:  BMC Infect Dis       Date:  2005-01-12       Impact factor: 3.090

5.  Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.

Authors:  Fred Stephen Sarfo; Maame Anima Sarfo; Betty Norman; Richard Phillips; George Bedu-Addo; David Chadwick
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 6.  Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.

Authors:  Opass Putcharoen; Tanya Do; Anchalee Avihingsanon; Kiat Ruxrungtham
Journal:  Drug Des Devel Ther       Date:  2015-10-23       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.